纳米雄黄对单纯疱疹病毒Ⅱ型的体外抗病毒活性

目的：探讨纳米雄黄对单纯疱疹病毒II型(herpes simplex virus Type II，HSV-2)的体外抗病毒活性。方法： 以阿昔洛韦作为阳性对照，采用噻唑蓝3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide，MTT]法观察 不同浓度(200.00，150.00，100.00，50.00，25.00，12.50，6.25，3.13，1.54，0.78，0.39和0 mg/L)纳米雄黄对正常非洲 绿源猴肾细胞(Vero细胞)作用48 h的细胞毒性；空斑法测定病毒滴度，建立病毒感染细胞模型，并采用细胞病变观 察和MTT结合的方法对不同浓度(20.00，10.00，5.00，2.50，1.25，0.63，0.31，0.15，0.08，0.04和0 mg/L)纳米雄黄在 预防、治疗及直接灭活病毒3种给药方式下的抗HSV-2活性进行评价。结果：纳米雄黄对正常Vero细胞的半数细胞毒 性浓度为37.15 mg/L，HSV-2病毒滴度为7.30 log PFUs/mL，纳米雄黄在预防、治疗和直接灭活病毒3种给药方式下对 HSV-2感染细胞的半数有效浓度分别为0.13，1.80和0.52 mg/L，对应的治疗指数分别为285.77，20.64和71.44，纳米雄 黄在预防给药下的治疗指数高于其治疗和直接灭活给药。结论：纳米雄黄在3种给药方式下均具有良好的抗HSV-2活 性，且预防给药的疗效较好。

Antiviral activity of nano-realgar against herpes simplex virus Type II in vitro

Objective: To explore the antiviral activity of nano-realgar against herpes simplex virus Type II (HSV-2) in vitro. Methods: Acyclovir (ACV) as a positive control, the cytotoxicity of nano-realgar at different concentrations (including 200.00, 150.00, 100.00, 50.00, 25.00, 12.50, 6.25, 3.13, 1.54, 0.78, 0.39 and 0 mg/L) on normal Vero cells were determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl- 2-H-tetrazolium bromide (MTT) assay. HSV-2 virus titer was determined by plaque assay, and the Vero cells model of HSV-2 infection was established. Subsequently, the antiviral effects of nano-realgar at different concentrations (including 20.00, 10.00, 5.00, 2.50, 1.25, 0.63, 0.31, 0.15, 0.08, 0.04 and 0 mg/L) on infected cells model were evaluated by the observation of cytopathic effect (CPE) and MTT method under the 3 modes including pre-treatment, treatment and direct inactivation. Results: The 50% cytotoxic concentration (CC50) of nano-realgar on Vero cells was 37.15 mg/L. The titer of HSV-2 was 7.30 log PFUs/mL. In the 3 modes, the half-maximal effective concentration (EC50) of nano-realgar on HSV-2 infected Vero cells were 0.13, 1.80 and 0.52 mg/L, and the corresponding therapeutic index (TI) were 285.77, 20.64, 71.44, respectively. The TI value of nano-realgar on pre-treatment mode was higher than that of nano-realgar on treatment and direct inactivation modes. Conclusion: Nano-realgar can play a good anti-HSV-2 activity in the 3 modes (pre-treatment, treatment and direct inactivation), and the anti-HSV-2 efficacy of nano-realgar on pre-treatment mode is better than that of nano-realagr on other 2 modes.